MARKET

NRBO

NRBO

NeuroBo Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.250
+0.240
+5.99%
After Hours: 4.260 +0.01 +0.24% 18:04 09/17 EDT
OPEN
3.960
PREV CLOSE
4.010
HIGH
4.289
LOW
3.927
VOLUME
52.50K
TURNOVER
--
52 WEEK HIGH
7.61
52 WEEK LOW
2.700
MARKET CAP
94.71M
P/E (TTM)
-2.4981
1D
5D
1M
3M
1Y
5Y
Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like
The big shareholder groups in NeuroBo Pharmaceuticals, Inc. ( NASDAQ:NRBO ) have power over the company. Institutions...
Simply Wall St. · 09/03 15:27
Innate Pharma, Tiziana Life Sciences leads healthcare gainers; Assembly Biosciences, Phreesia among major losers
Gainers: Innate Pharma (NASDAQ:IPHA) +32%, Tiziana Life Sciences (NASDAQ:TLSA) +16%, Verrica Pharmaceuticals (NASDAQ:VRCA) +12%, NeuroBo Pharmaceuticals (NASDAQ:NRBO) +12%, Scopus BioPharma (NASDAQ:SCPS) +11%. Losers: Assembly Biosciences (NASDAQ:ASMB) -17...
Seekingalpha · 09/02 15:07
BRIEF-Dong-A St Co Ltd Submitted A Non-Binding Proposal To NeuroBo Pharmaceuticals Board With Respect To Potential Licensing Transaction
reuters.com · 09/01 22:23
12 Health Care Stocks Moving In Tuesday's After-Market Session
 Gainers  
Benzinga · 08/17 20:41
NeuroBo Pharmaceuticals EPS misses by $0.03
NeuroBo Pharmaceuticals (NASDAQ:NRBO): Q2 GAAP EPS of -$0.18 misses by $0.03. Cash and Cash Equivalents were $9.5 million as of June 30, 2021, compared with $10.1 million as of December
Seekingalpha · 08/16 12:41
NeuroBo Pharmaceuticals Q2 EPS $(0.18) Down From $(0.15) YoY
NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(0.18) per share. This is a 20 percent decrease over losses of $(0.15) per share from the same period last year.
Benzinga · 08/16 12:24
NeuroBo Pharma European Patent Specification Doc For Co.'s 'COMPOSITION CONTAINING PORIA COCOS BARK EXTRACT FOR PREVENTING, IMPROVING OR TREATING NEURODEGENERATIVE DISORDERS'
https://data.epo.org/publication-server/pdf-document?pn=3632454&ki=B1&cc=EP
Benzinga · 08/11 14:03
Seres Therapeutics, IAMGOLD, PBF Energy among premarket losers' pack
Seres Therapeutics MCRB -57% after mid-stage ulcerative colitis study fails main goal.Jupiter Wellness JUPW -24% after raises $32.5M capital via stock and warrants offering.TRACON Pharmaceuticals TCON -23% after securing $15M capital raise.NETGEAR NTGR -15...
Seekingalpha · 07/22 12:25
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NRBO. Analyze the recent business situations of NeuroBo Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NRBO stock price target is 16.00 with a high estimate of 16.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 3.54M
% Owned: 15.88%
Shares Outstanding: 22.29M
TypeInstitutionsShares
Increased
4
30.35K
New
10
188.02K
Decreased
11
558.93K
Sold Out
14
292.55K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Director
Douglas Swirsky
President/Chief Executive Officer/Chief Financial Officer/Treasurer/Secretary/Director
jeong Gu Kang
Chief Operating Officer/Senior Vice President
Akash Bakshi
Senior Vice President
Andrew Bartynski
Senior Vice President
Nadja Mannowetz
Director
Na Yeon Kim
Independent Director
Jason Groves
Independent Director
Hyung Kim
Independent Director
Andrew Koven
Independent Director
Michael Salsbury
No Data
About NRBO
NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. The Company is focused on developing pharmaceuticals to treat neurodegenerative disorders. The Company is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. The Company’s product candidate, NB-01, is targeting neuropathic pain with an indication in PDN. The Company also provides NB-02, which is an Alzheimer’s and tauopathies drug. Its product candidate Gemcabene is focused on developing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications such as homozygous familial hypercholesterolemia (HoFH), as well as severe hypertriglyceridemia (SHTG). It also focused on developing capsule formulation of niclosamide for coronavirus indications.

Webull offers kinds of Neurobo Pharmaceuticals Inc stock information, including NASDAQ:NRBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRBO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NRBO stock methods without spending real money on the virtual paper trading platform.